Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as VY1706 Low dose, VY1706 Mid dose
VY1706 · 1 trial · 1 indication
Incidence of treatment emergent adverse events, clinically significant changes from baseline in vital signs, physical and neurological exams, Columbia Suicide-Severity Rating Scale, Electrocardiogram, Clinical lab parameters and transthoracic echocardiogram
| Arm | Type | Description |
|---|---|---|
| Low dose IV Infusion | EXPERIMENTAL | - |
| Mid dose IV Infusion | EXPERIMENTAL | - |
| High dose IV Infusion | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| VY1706 Low dose | DRUG | Low dose |
| VY1706 Mid dose | DRUG | Mid Dose |
| VY1706 High Dose | DRUG | High dose |
| Anti-AAV9 Total Antibody (TAb) Assay | DEVICE | Anti-AAV9 Total Antibody (TAb) Assay |
Inclusion Criteria: * Male or female participants aged 55 to 80 years (inclusive) at Screening or aged 30 to 80 years (inclusive) if presence of a historically documented dominantly inherited mutation associated with monogenic AD. * Clinical diagnosis of mild cognitive impairment (MCI) due to AD or...
Top 20 of 24 competitors
VY1706 Low dose is an investigational small molecule being studied for the treatment of early Alzheimer's Disease. It is currently in Phase 1 clinical development, with an open-label dose escalation study recruiting participants who have early-stage Alzheimer's Disease.
VY1706 Low dose targets MAPT, the gene that encodes the tau protein. By targeting MAPT, the drug aims to address tau-related pathology, which is a key feature of Alzheimer's Disease. This mechanism is being evaluated in a Phase 1 clinical trial for early Alzheimer's Disease.
VY1706 Low dose is being developed by Voyager Therapeutics, Inc., a biopharmaceutical company traded on NASDAQ under the ticker symbol VYGR. The company is conducting a Phase 1 clinical trial of VY1706 Low dose in participants with early Alzheimer's Disease.
VY1706 Low dose is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. A Phase 1 open-label dose escalation study is currently recruiting participants with early Alzheimer's Disease in the United States.
VY1706 Low dose is being evaluated in one active clinical trial, NCT07764146, titled 'An Open Label Dose Escalation Study of VY1706 in Participants With Early Alzheimer's Disease.' This Phase 1 study is recruiting 18 participants aged 30 years and older in the United States.